Twist Bioscience
In Brief This Week: Ultima Genomics, Scale Bio, Mainz Biomed, Eurofins, Synlab, GenomeDE, More
News items for the week of March 31, 2025.
Twist Bioscience Raises Fiscal 2025 Guidance as Q1 Revenues Rise 24 Percent
The synthetic biology and genomics company reported 24 percent year-over-year revenue growth in fiscal Q1, beating Wall Street expectations.
JP Morgan Healthcare Conference, Day 1: Oxford Nanopore, 10x Genomics, Bruker, Qiagen, More
Highlights from the first day included Exact Sciences' plan to launch three new cancer tests in 2025 and Qiagen's sample prep launch plans for 2026.
Wolfe Research Begins Coverage of Hologic at Peer Perform, Tempus and Twist Bioscience at Outperform
Analyst Doug Schenkel said that Tempus has a broad and growing menu and Twist Bio has developed a novel DNA synthesis platform. He set $60 price targets for those companies.
Twist Bioscience Fiscal Q4 Revenues Jump 27 Percent
The South San Francisco, California-based firm booked $84.7 million in revenues for fiscal Q4 revenues and $313.0 million for FY 2024, both record numbers for the company.
Oct 21, 2024